References
- Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153–66
- Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 2005;5:366–73
- Malumbres M, Barbacid M. Mammalian. Cyclin dependent kinases. Trends Biochem Sci 2005;30;630–41
- Tsutsui T, Hesabi B, Moons DS, et al. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol 1999;19:7011–19
- Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003;3:233–45
- Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131–49
- de Cárcer G, Pérez de Castro I, Malumbres M. Targeting cell cycle kinases for cancer therapy. Curr Med Chem 2007;14:969–85
- Orzáez M, Gortat A, Mondragón L, et al. ATP-noncompetitive inhibitors of CDK-cyclin complexes. ChemMedChem 2009;4:19–24
- D'Alessio R, Bargiotti A, Metz S, et al. Benzodipyrazoles: a new class of potent CDK2 inhibitors. Bioorg Med Chem Lett 2005;15:1315–19
- Ligprep, version 2.6. NewYork: Schrödinger, LLC; 2013. (http://www.schrodinger.com/LigPrep/)
- Phase, Version 3.5. NewYork: Schrodinger, LLC; 2013. (http://www.schrodinger.com/Phase/)
- Dixon SL, Smondyrev AM, Knoll EH, et al. PHASE: a novel approach to pharmacophore modeling and 3D database searching. J Comput Aided Mol Des 2006;20:647–71
- Rajendra Prasad VV, Deepak Reddy G, Appaji D, et al. Chemosensitizing acridones: in vitro calmodulin dependent cAMP phosphodiesterase inhibition, docking, pharmacophore modeling and 3D QSAR studies. J Mol Graph Model 2013;40:116–24
- Golbraikh A, Tropsha A. Beware of q2!. J Mol Graph Model 2002;20:269–76
- Friesner RA, Murphy RB, Repasky MP, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein−ligand complexes. J Med Chem 2006;49:6177–96
- Guimarães CR. MM-GBSA rescoring of docking poses. Methods Mol Biol 2012;819:255–68
- Muñoz C, Adasme F, Alzate-Morales JH, et al. Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations. J Mol Graph Model 2012;32:39–48
- Desmond molecular dynamics system, version 3.9. New York, NY: D. E. Shaw Research; 2014. (http://www.deshawresearch.com/resources_desmond.html)
- Shivakumar D, Harder E, Damm W, et al. Improving the prediction of absolute solvation free energies using the next generation OPLS force field. J Chem Theory Comput 2012;8:2553–8